In pancreatic cancer cells, the formation of EGFR/ErbB3 heterodimers are also evidenced to influence the pancreatic cancer cells’ sensitivity to erlotinib [34]. This evidence concerns the gene ERBB3 and familial pancreatic carcinoma.